| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.51 | 0.0007 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0007 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |